Compare RTB & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTB | CING |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.2M | 64.5M |
| IPO Year | N/A | N/A |
| Metric | RTB | CING |
|---|---|---|
| Price | $17.00 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 88.6K | ★ 168.9K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.14 | $3.16 |
| 52 Week High | $20.75 | $11.89 |
| Indicator | RTB | CING |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 57.73 |
| Support Level | $13.32 | $4.80 |
| Resistance Level | $19.98 | $5.15 |
| Average True Range (ATR) | 2.27 | 0.28 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 35.89 | 94.15 |
RTB Digital Inc is focused on developing and operating a professional SaaS (Software as a Service) platform which hosts an exclusive coalition of professionally-managed online media channels. Its operations include software development, advertising and sponsorship sales, and onboarding third-party content operators (Platform Partners) to publish content on the platform.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.